FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807862033> ?p ?o ?g. }

• W2807862033 endingPage "2205" @default.
• W2807862033 startingPage "2197" @default.
• W2807862033 abstract "Abstract Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)-targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between therapies. We have developed several models representing CRPC with acquired therapeutic resistance. Here, we utilized these models to assess putative cross-resistance between treatments. We find that resistance to enzalutamide induces resistance to abiraterone and vice versa, but resistance to neither alters sensitivity to taxanes. Acquired resistance to docetaxel induces cross-resistance to cabazitaxel but not to enzalutamide or abiraterone. Correlating responses with known mechanisms of resistance indicates that AR variants are associated with resistance to NGATs, whereas the membrane efflux protein ABCB1 is associated with taxane resistance. Mechanistic studies show that AR variant-7 (AR-v7) is involved in NGAT resistance but not resistance to taxanes. Our findings suggest the existence of intra cross-resistance within a drug class (i.e., within NGATs or within taxanes), whereas inter cross-resistance between drug classes does not develop. Furthermore, our data suggest that resistance mechanisms differ between drug classes. These results may have clinical implications by showing that treatments of one class can be sequenced with those of another, but caution should be taken when sequencing similar classed drugs. In addition, the development and use of biomarkers indicating resistance will improve patient stratification for treatment. Mol Cancer Ther; 17(10); 2197–205. ©2018 AACR." @default.
• W2807862033 created "2018-06-21" @default.
• W2807862033 creator A5007026296 @default.
• W2807862033 creator A5012734277 @default.
• W2807862033 creator A5035270770 @default.
• W2807862033 creator A5048369552 @default.
• W2807862033 creator A5058036624 @default.
• W2807862033 creator A5074725449 @default.
• W2807862033 creator A5086066594 @default.
• W2807862033 creator A5087359161 @default.
• W2807862033 creator A5088621070 @default.
• W2807862033 date "2018-10-01" @default.
• W2807862033 modified "2023-09-27" @default.
• W2807862033 title "Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer" @default.
• W2807862033 cites W1654777185 @default.
• W2807862033 cites W1844925317 @default.
• W2807862033 cites W1967774964 @default.
• W2807862033 cites W1969172484 @default.
• W2807862033 cites W1969202480 @default.
• W2807862033 cites W1971322201 @default.
• W2807862033 cites W1992624438 @default.
• W2807862033 cites W2004361934 @default.
• W2807862033 cites W2007334137 @default.
• W2807862033 cites W2014077960 @default.
• W2807862033 cites W2017919614 @default.
• W2807862033 cites W2045589622 @default.
• W2807862033 cites W2055346449 @default.
• W2807862033 cites W2075004958 @default.
• W2807862033 cites W2092769920 @default.
• W2807862033 cites W2096795721 @default.
• W2807862033 cites W2108679313 @default.
• W2807862033 cites W2119504728 @default.
• W2807862033 cites W2120292596 @default.
• W2807862033 cites W2123526148 @default.
• W2807862033 cites W2123629153 @default.
• W2807862033 cites W2148643283 @default.
• W2807862033 cites W2155466895 @default.
• W2807862033 cites W2157980218 @default.
• W2807862033 cites W2165823301 @default.
• W2807862033 cites W2166918329 @default.
• W2807862033 cites W2168108459 @default.
• W2807862033 cites W2170668585 @default.
• W2807862033 cites W2267810789 @default.
• W2807862033 cites W2302309747 @default.
• W2807862033 cites W2320590135 @default.
• W2807862033 cites W2404460725 @default.
• W2807862033 cites W2419426348 @default.
• W2807862033 cites W2509022872 @default.
• W2807862033 cites W2530715453 @default.
• W2807862033 cites W2538867449 @default.
• W2807862033 cites W2552482676 @default.
• W2807862033 cites W2613775504 @default.
• W2807862033 cites W2735934083 @default.
• W2807862033 cites W2740979023 @default.
• W2807862033 cites W913623683 @default.
• W2807862033 doi "https://doi.org/10.1158/1535-7163.mct-17-1269" @default.
• W2807862033 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6168406" @default.
• W2807862033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29891490" @default.
• W2807862033 hasPublicationYear "2018" @default.
• W2807862033 type Work @default.
• W2807862033 sameAs 2807862033 @default.
• W2807862033 citedByCount "27" @default.
• W2807862033 countsByYear W28078620332018 @default.
• W2807862033 countsByYear W28078620332019 @default.
• W2807862033 countsByYear W28078620332020 @default.
• W2807862033 countsByYear W28078620332021 @default.
• W2807862033 countsByYear W28078620332022 @default.
• W2807862033 countsByYear W28078620332023 @default.
• W2807862033 crossrefType "journal-article" @default.
• W2807862033 hasAuthorship W2807862033A5007026296 @default.
• W2807862033 hasAuthorship W2807862033A5012734277 @default.
• W2807862033 hasAuthorship W2807862033A5035270770 @default.
• W2807862033 hasAuthorship W2807862033A5048369552 @default.
• W2807862033 hasAuthorship W2807862033A5058036624 @default.
• W2807862033 hasAuthorship W2807862033A5074725449 @default.
• W2807862033 hasAuthorship W2807862033A5086066594 @default.
• W2807862033 hasAuthorship W2807862033A5087359161 @default.
• W2807862033 hasAuthorship W2807862033A5088621070 @default.
• W2807862033 hasBestOaLocation W28078620331 @default.
• W2807862033 hasConcept C114851261 @default.
• W2807862033 hasConcept C121608353 @default.
• W2807862033 hasConcept C126322002 @default.
• W2807862033 hasConcept C143998085 @default.
• W2807862033 hasConcept C2776421732 @default.
• W2807862033 hasConcept C2776551883 @default.
• W2807862033 hasConcept C2777511904 @default.
• W2807862033 hasConcept C2777899217 @default.
• W2807862033 hasConcept C2778971682 @default.
• W2807862033 hasConcept C2780192828 @default.
• W2807862033 hasConcept C2781190966 @default.
• W2807862033 hasConcept C502942594 @default.
• W2807862033 hasConcept C530470458 @default.
• W2807862033 hasConcept C54355233 @default.
• W2807862033 hasConcept C61367390 @default.
• W2807862033 hasConcept C71924100 @default.
• W2807862033 hasConcept C86803240 @default.
• W2807862033 hasConcept C98274493 @default.
• W2807862033 hasConceptScore W2807862033C114851261 @default.

• next